Blood pressure response to an angiotensin II antagonist in patients with acromegaly. 1979

T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara

The renin-angiotensin-aldosterone system in patients with acromegaly was evaluated by infusing [sarcosine1, isoleucine8]angiotensin II, a competitive angiotensin II antagonist, into five acromegalic patients with hypertension and three normotensive acromegalics. The drug was infused at a rate of 600 ng/kg . min for 30 min, 1 h after iv injection of 40 mg furosemide. In addition, before the infusion, plasma samples were obtained for determination of PRA and plasma aldosterone concentration. A significant pressor response to [sarcosine1, isoleucine8]angiotensin II was observed in all eight patients. Preinfusion PRA and plasma aldosterone concentration were significantly lower than in normal controls. It is concluded that in acromegaly, the renin-angiotensin-aldosterone system is suppressed and that this system is probably not involved in maintenance of the high blood pressure observed in some acromegalic patients.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara
August 1980, The Journal of clinical endocrinology and metabolism,
T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara
September 1976, The Journal of clinical endocrinology and metabolism,
T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara
October 2001, Journal of hypertension,
T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara
April 1997, Journal of cardiovascular pharmacology,
T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara
June 2001, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara
December 1994, European journal of endocrinology,
T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara
May 1995, The Journal of pharmacology and experimental therapeutics,
T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara
January 2007, European journal of clinical pharmacology,
T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara
January 1966, Surgical forum,
T Ogihara, and T Hata, and A Maruyama, and H Mikami, and M Nakamaru, and Y Okada, and Y Kumahara
January 1981, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!